Apr 23, 2021 / 04:00PM GMT
Operator
Welcome, everyone, to the Brickell Biotech Phase III open-label long-term safety study data conference call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to turn the call over to Dan Ferry from LifeSci Advisors. Dan?
Daniel Ferry - LifeSci Advisors, LLC - MD & Relationship Manager
Thank you, and good afternoon, everyone. Joining us on today's call is Dr. Stacy Smith, Head of the California Dermatology and Clinical Research Institute and an investigator in the Phase III open-label, long-term safety study. Representing the company on today's call, we have Brickell's Chief Executive Officer, Rob Brown, and Chief R&D Officer, Deepak Chadha.
Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of the date of this call. We
Brickell Biotech Inc Long Term Safety Study Results for Sofpironium Bromide Gel Corporate Call Transcript
Feb 13, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers